Panacea Biotec Limited – Product Pipeline Review

Global Markets Direct’s, ‘Panacea Biotec Limited – Product Pipeline Review – 2016’, provides an overview of the Panacea Biotec Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Panacea Biotec Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Panacea Biotec Limited

The report provides overview of Panacea Biotec Limited including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Panacea Biotec Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Panacea Biotec Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Panacea Biotec Limited’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Panacea Biotec Limited

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Panacea Biotec Limited’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Panacea Biotec Limited Snapshot 7

Panacea Biotec Limited Overview 7

Key Information 7

Key Facts 7

Panacea Biotec Limited - Research and Development Overview 8

Key Therapeutic Areas 8

Panacea Biotec Limited - Pipeline Review 12

Pipeline Products by Stage of Development 12

Pipeline Products - Monotherapy 13

Pipeline Products - Combination Treatment Modalities 14

Panacea Biotec Limited - Pipeline Products Glance 15

Panacea Biotec Limited - Late Stage Pipeline Products 15

Phase III Products/Combination Treatment Modalities 15

Panacea Biotec Limited - Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Panacea Biotec Limited - Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Discovery Products/Combination Treatment Modalities 19

Panacea Biotec Limited - Unknown Stage Pipeline Products 20

Unknown Products/Combination Treatment Modalities 20

Panacea Biotec Limited - Drug Profiles 21

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

polio [strain Sabin] vaccine 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Nucovac 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

bevacizumab biosimilar 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

cetuximab biosimilar 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

darbepoetin alfa 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

etanercept biosimilar 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

hepatitis B vaccine 2 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Monoclonal Antibodies for Cancer 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

omalizumab biosimilar 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

rituximab biosimilar 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Synthetic Peptide for Alopecia 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

trastuzumab biosimilar 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

dengue (tetravalent) vaccine 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

influenza vaccine 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Japanese encephalitis vaccine 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

meningococcal vaccine 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

pertussis (acellular) vaccine 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

pneumococcal vaccine 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

respiratory syncytial virus vaccine 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Synthetic Peptides to Agonize GLP-1 for Type 2 Diabetes 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

yellow fever vaccine 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Recombinant Protein for Autoimmune Disorders 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Recombinant Protein for Renal Anemia 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Panacea Biotec Limited - Pipeline Analysis 46

Panacea Biotec Limited - Pipeline Products by Target 46

Panacea Biotec Limited - Pipeline Products by Route of Administration 47

Panacea Biotec Limited - Pipeline Products by Molecule Type 48

Panacea Biotec Limited - Pipeline Products by Mechanism of Action 49

Panacea Biotec Limited - Recent Pipeline Updates 50

Panacea Biotec Limited - Dormant Projects 51

Panacea Biotec Limited - Company Statement 52

Panacea Biotec Limited - Locations And Subsidiaries 53

Head Office 53

Other Locations & Subsidiaries 53

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55

List of Tables

List of Tables

Panacea Biotec Limited, Key Information 7

Panacea Biotec Limited, Key Facts 7

Panacea Biotec Limited – Pipeline by Indication, 2016 9

Panacea Biotec Limited – Pipeline by Stage of Development, 2016 12

Panacea Biotec Limited – Monotherapy Products in Pipeline, 2016 13

Panacea Biotec Limited – Combination Treatment Modalities in Pipeline, 2016 14

Panacea Biotec Limited – Phase III, 2016 15

Panacea Biotec Limited – Phase II, 2016 16

Panacea Biotec Limited – Phase I, 2016 17

Panacea Biotec Limited – Preclinical, 2016 18

Panacea Biotec Limited – Discovery, 2016 19

Panacea Biotec Limited – Unknown, 2016 20

Panacea Biotec Limited – Pipeline by Target, 2016 46

Panacea Biotec Limited – Pipeline by Route of Administration, 2016 47

Panacea Biotec Limited – Pipeline by Molecule Type, 2016 48

Panacea Biotec Limited – Pipeline Products by Mechanism of Action, 2016 49

Panacea Biotec Limited – Recent Pipeline Updates, 2016 50

Panacea Biotec Limited – Dormant Developmental Projects,2016 51

Panacea Biotec Limited, Other Locations 53

Panacea Biotec Limited, Subsidiaries 53

List of Figures

List of Figures

Panacea Biotec Limited – Pipeline by Top 10 Indication, 2016 9

Panacea Biotec Limited – Pipeline by Stage of Development, 2016 12

Panacea Biotec Limited – Monotherapy Products in Pipeline, 2016 13

Panacea Biotec Limited – Pipeline by Top 10 Target, 2016 46

Panacea Biotec Limited – Pipeline by Route of Administration, 2016 47

Panacea Biotec Limited – Pipeline by Top 10 Molecule Type, 2016 48

Panacea Biotec Limited – Pipeline Products by Mechanism of Action, 2016 49

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports